Skip to main content
CND In the News

Featured on WFSB News in Hartford

By December 8, 2022January 6th, 2023No Comments

Featured on WFSB News in Hartford

Dr. Toni De Marcaida, Medical Director of Hartford Healthcare’s Chase Family Movement Disorders Center in Hartford, CT, spoke this week on WFSB Channel 3 News about the positive impact the Syn-One Test has had on her practice and patients. “This is a test that has never been available to us as clinicians before.”

The story highlights the experience of Jon Kugelman, a 77-year-old who had been struggling with movement-related symptoms for years without a diagnosis. That changed earlier this year when Dr. Marcaida was able to offer him the Syn-One Test and confirm a diagnosis of Parkinson’s disease.

Parkinson’s can be challenging to diagnose in cases where patients present with uncommon symptoms or symptoms that overlap with other neurological disorders. The Syn-One Test from CND Life Sciences provides visual proof of the presence of a misfolded protein—phosphorylated alpha-synuclein—a hallmark of a group of neurological disorders that includes Parkinson’s disease.

A definitive diagnosis arms clinicians with the information they need to recommend an appropriate treatment plan and can provide closure for patients. “I just feel that it’s better to know what you’re up against rather than always be wondering,” said Jon.

Watch the story

CND Life Sciences

CND Life Sciences is the creator of the Syn-One Test™, the world’s first commercially available test to visualize abnormal, phosphorylated alpha-synuclein in cutaneous nerve fibers. The test is an objective, evidence-based diagnostic tool to aid in the diagnosis of Parkinson’s disease, dementia with Lewy bodies, multiple system atrophy, pure autonomic failure, or REM sleep behavior disorder.